Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates

Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria

(2010) Antonia C. Kastoris et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin

(2010) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections

(2010) Alexandro Rodríguez-Rojas et al.   PLoS One

Prospective Observational Study of the Impact of VIM-1 Metallo- -Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream Infections

(2009) G. L. Daikos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation

(2009) A. Michalopoulos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Role of Old Antibiotics in Multidrug Resistant Bacterial Infections

(2009) R. Maviglia et al.   CURRENT DRUG TARGETS

Fosfomycin: an old, new friend?

(2009) M. Popovic et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

(2009) Nikos Roussos et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

(2009) D. L. MacLeod et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

(2009) Patrice Nordmann et al.   LANCET INFECTIOUS DISEASES

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review

(2009) Matthew E Falagas et al.   LANCET INFECTIOUS DISEASES

Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal Infections

(2008) Matthew E. Falagas et al.   CLINICAL INFECTIOUS DISEASES

Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gram‐Negative Bacilli: Need for International Harmonization in Terminology

(2008) Matthew E. Falagas et al.   CLINICAL INFECTIOUS DISEASES